Navigation Links
Vasomedical Announces Share Repurchase Program of up to $1.5 Million in Common Stock
Date:4/1/2013

WESTBURY, N.Y., April 1, 2013 /PRNewswire/ -- Vasomedical, Inc. (OTC BB: VASO), announced today that its Board of Directors has authorized a share repurchase program of up to $1.5 million of the Company's common stock. As of Friday, March 29, 2013, this would represent approximately 5% of the total outstanding shares of Vasomedical common stock.

"We have the capital resources available to implement a fairly aggressive stock repurchase program such as this, which amounts to roughly 5% of our total outstanding shares, and still invest in our company's business to drive future growth. We believe that our share price does not properly reflect the current value of our business or its potential future performance," said Dr. Jun Ma , President and Chief Executive Officer of Vasomedical, Inc. "We have a strong financial profile that gives us the flexibility to focus on our future plans to grow sales and achieve profitability, while supporting our stock. We believe this strategy shows our commitment to building shareholder value as well as confidence in achieving long-term growth."  

The share repurchase program is effective immediately. Repurchases will be made in accordance with applicable securities laws in the open market or in privately negotiated transactions. Depending on market conditions and other factors, these repurchases may be commenced or suspended from time to time without prior notice. The Company is under no obligation to fulfill the entire amount of the stock buyback program approved by the Board.

About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products.  The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned
'/>"/>

SOURCE Vasomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vasomedical Announces Financial Results for the Fourth Quarter and Year Ended 2012
2. Vasomedical to Report Fourth Quarter and Year End 2012 Results on April 1, 2013
3. Vasomedical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
4. Vasomedical, Inc. to Present Live Webcast at RetailInvestorConferences.com on February 7th
5. The International EECP Therapists Association and Vasomedical Announce Second Annual EECP Therapy Week
6. Vasomedical Common Stock Commences Trading on the OTCBB
7. Vasomedical Announces Financial Results for the Third Quarter of 2012
8. Vasomedical Named on Deloittes 2012 Technology Fast 500 List
9. Vasomedical Retains KCSA Strategic Communications as Corporate Communications Counsel
10. Bovie Medical Corporation Announces Fiscal Year 2012 Financial Results
11. Cardiac Science announces definitive agreement to sell its Diagnostic Cardiology product line to Mortara Instrument, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... is pleased to announce the appointment of Dr. ... Biochemistry. Scott joins the company after previous scientific leadership positions ... course of his nearly 20 year career in therapeutics ... recognized thought leader in the biosensor field and particularly ...
(Date:1/22/2015)... Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... on Omega-3 therapies for cardiovascular disease and overall health is ... accomplishments in 2014 and its outlook for 2015 from the ... Shareholders, We would like to take this opportunity ...
(Date:1/22/2015)... 2015  Profil Institute for Clinical Research, Inc., a clinical ... today a new textbook,  Translational Research Methods for Diabetes, ... leading global scientific publisher. The textbook is ... use in early phase clinical studies of new drugs ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... Response Rate,in Two Clinical Trials , Clinical Data ... Exelixis Reports Comprehensive XL880 Phase I Data At ... II Clinical Trials,of XL999 at ASCO , Clinical ... Solid Tumors , Studies Investigating Vidaza in Alternate ...
... Presented at the , 2007 American Society of ... Older Patients with AML and in,Refractory , ALL ... of Aloxi(R),with , the 5-HT3 Receptor Reported-- , ... , with Multimodal Therapy, including Gliadel(R) Described-- , ...
Cached Medicine Technology:Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 2Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 3Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 4Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 5Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 6Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 7Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 8Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 9Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 10Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 11Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 12Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 13Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 14Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 15Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 16Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 17Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 18Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 19Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 20Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 21Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 22Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 23Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 24Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 25Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 26Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 27Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 28Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors 29MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 8
(Date:1/22/2015)... January 22, 2015 Deer Path of Huntley ... a Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. ... Regency Parkway in Huntley, Illinois, serves adults with physical disabilities between ... will include Valentine's Day treats, games and sweetheart-themed karaoke. , For ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located ... the number one best large hotel for families in the ... their annual Travelers’ Choice Awards. , TripAdvisor represents the ... home to millions of unbiased and honest traveler reviews. The ...
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... PHILADELPHIA, Nov. 6 In a newly-published special supplement, ... policies to prevent and treat venous thromboembolism (VTE), a ... the world. Lippincott Williams & Wilkins (LWW) ... a disease that includes both the common medical condition ...
... Nov. 6 The American Academy of Nursing ... of Lippincott Williams & Wilkins (LWW) nursing publications ... Kluwer Health, a leading provider of information and ... medicine, nursing, allied health, and pharmacy. Academy Fellows ...
... DALLAS, Nov. 6 Lockton Benefit Group, the ... Companies, LLC, today announced employer health cost reduction ... U.S.-based healthcare company Concentra. , (Logo: ... a services provider to support Lockton,s clients with: ...
... play a role in boosting memories -- or forgetting them, ... Do you remember the first time you smelled a type ... that your brain might. , In the study, published ... researchers showed objects to adult study participants. They paired the ...
... to bronchiolitis, study finds , FRIDAY, Nov. 6 (HealthDay ... traffic as a risk factor for bronchiolitis, the respiratory ... the first year of life, a new study finds. ... appliances were more likely to show up in doctors, ...
... Researchers at Wake Forest University School of Medicine and the ... (PSA) levels in men may be caused by a hormone ... predictor of the need for a prostate biopsy. ... potential sign of prostate cancer, leading to the widespread use ...
Cached Medicine News:Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 2Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 3Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 2Health News:Seven LWW Nursing Editors Recognized as Leaders by American Academy of Nursing 3Health News:Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 2Health News:Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 3Health News:New Smells 'Etched' in Brain: Study 2Health News:Wood Fires Can Harm the Youngest Lungs 2Health News:New finding suggests prostate biopsy is not always necessary 2Health News:New finding suggests prostate biopsy is not always necessary 3
... The EndoProbe handpieces, used for endophotocoagulation ... aspiration, 25 gauge, and illuminating models. ... the ophthalmologist with uncompromised laser treatment ... 3-meter, fiber-optic cables that are flexible ...
... The Rare Earth Intraocular Magnet is especially ... intraocular foreign bodies. The precise, sleek design ... commonly observed with electromagnetic devises. Due to ... minimizes the possibility of secondary foreign body ...
... On-line Electronic Help (OLEH), an ... to critical anesthesia-related information. OLEH brings ... need it most right on ... care of the patient and ...
... High-performance monitoring for flexible care settings., ... monitors combine portability and measurement flexibility ... needs of intermediate care environmentsat the ... strong heritage in patient monitoring, IntelliVue ...
Medicine Products: